Karyopharm to Present Selinexor Phase 2 SEAL Data at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
229
Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting

NEWTON, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2018 Annual Meeting taking place June 1-5, 2018 in Chicago.  Among the poster presentations will be results from the Company’s Phase 2 SEAL study evaluating selinexor, its lead, oral SINE compound, in patients with advanced de-differentiated liposarcoma.  The remaining posters will highlight clinical and preclinical data from ongoing investigator-sponsored trials evaluating selinexor in combination with other anti-cancer agents.

“Dedifferentiated liposarcoma is a rare and aggressive form of the disease that is resistant to both standard chemotherapy and radiation, and most patients who progress following surgery ultimately succumb to this difficult to treat cancer,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm.  “We previously reported positive top-line data from the Phase 2 SEAL study in September 2017, including oral selinexor’s demonstration of superiority over placebo for the study’s primary endpoint of progression-free survival (PFS), with a hazard ratio of 0.60, representing a 40% reduction in the risk of progression or death.  The Phase 3 portion of the SEAL study is currently ongoing with top-line data expected by the end of 2019.  We look forward to presenting the more detailed results from the Phase 2 portion of the SEAL study at ASCO this year.”

Details for the ASCO 2018 selinexor presentations are as follows:

Company-sponsored Trials

Title:   Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study Lead author: Mrinal Gounder, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College Poster Board #: 257 Abstract #: 11512 Poster Discussion Session: Sarcoma Date and Time: Saturday, June 2, 2018; 8:00 AM – 11:30 AM CT; Discussion from 3:00 PM – 4:15PM Location: Hall A

Investigator-sponsored Trials

Title: Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia Lead author: Bhavana Bhatnagar, Ohio State University Comprehensive Cancer Center Poster Board #: 108 Abstract: 7048 Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date and Time: Monday, June 4, 2018; 8:00 AM – 11:30 AM CT Location: Hall A

Title: Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS) Lead author: Eoghan Ruadh Malone, Princess Margaret Cancer Centre Poster Board #: 307 Abstract: 11562 Poster Session: Sarcoma Date and Time: Saturday, June 2, 2018; 8:00 AM – 11:30 AM CT Location: Hall A

Title: Profiling the immune checkpoint pathway in acute myeloid leukemia Lead author: Paola Dama, University of Chicago Poster Board #: 75 Abstract: 7015 Poster Discussion Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant Date and Time: Monday, June 4, 2018; 8:00 AM – 11:30 AM CT; Discussion from 11:30 AM – 12:45 PM CT Location: Hall A

About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, over 2,400 patients have been treated with selinexor. In April 2018, Karyopharm reported positive top-line data from the Phase 2b STORM study evaluating selinexor in combination with low-dose dexamethasone in patients with penta-refractory multiple myeloma. Selinexor has been granted Orphan Drug Designation in multiple myeloma and Fast Track designation for the patient population evaluated in the STORM study.  Karyopharm plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second half of 2018, with a request for accelerated approval for oral selinexor as a new treatment for patients with penta-refractory multiple myeloma.  The Company also plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in early 2019 with a request for conditional approval.  Selinexor is also being evaluated in several other mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON) and as a potential backbone therapy in combination with approved therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL), liposarcoma (SEAL), and an investigator-sponsored study in endometrial cancer (SIENDO), among others.  Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform Karyopharm's clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov .

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the timing of submissions to regulatory authorities and the potential availability of accelerated approval pathways, the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases, that development of any of Karyopharm's drug candidates will continue or that any feedback from regulatory authorities will ultimately lead to the approval of selinexor or any of Karyopharm’s other drug candidates. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on May 10, 2018, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited

Contacts:

Investors: Kimberly Minarovich (646) 368-8014 kimberly@argotpartners.com  

Mary Jenkins (617) 340-6073 mary@argotpartners.com

Media: David Rosen (212) 600-1902 david.rosen@argotpartners.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 27

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 46

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
SeoulTech's Liver Chip Makes Toxicity Testing Practical

Updated Category News Views 32

A Lab Tool Finally Built for the Messy Part Thousands of everyday chemicals are floating around commerce with thin toxicity records, and that is a lousy way to run a modern economy. Seoul National University of Science and Technology researchers have put forward a modular liver-on-a-chip platform aimed squarely at that gap: making environmental chemical testing more...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 111

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 93

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Workers Unite in Major Strike Action Ahead of Holidays

Updated Category News Views 645

Starbucks Workers Prepare for Significant Strike Starbucks (NASDAQ: SBUX) workers, represented by a union encompassing more than 10,000 individuals, have announced plans for a strike in major cities like Los Angeles, Chicago, and Seattle. This strike is set to commence on Friday and is expected to last through the busy Christmas season. Union's Demands for Better...

Continue Reading
Discover Häagen-Dazs® Summer Blueberry Collection Now!

Updated Category News Views 140

Häagen-Dazs® Shops Launches Delicious Summer Blueberry Collection The summer season is here, and Häagen-Dazs® Shops embraces it with their enticing Summer Blueberry Collection. This delightful selection is all about providing a refreshing and revitalizing experience for ice cream lovers. With an exquisite range of flavors, including the brand's first-ever oat...

Continue Reading
Innovative Beef Supply Chain By Rancher's Sustainable Angus Alliance

Updated Category News Views 240

Transforming the Beef Supply Chain for Sustainability The Rancher's Sustainable Angus Alliance (RSAA) is actively engaging with beef retail partners who are committed to delivering top-notch Angus beef while emphasizing animal welfare and environmental responsibility. Founded by a group of visionary seedstock ranchers, RSAA aims to connect consumers with the rich heritage...

Continue Reading
Emerging Trends and Growth in Global Glucose Testing Market

Updated Category News Views 131

Overview of the Global Point-of-Care Glucose Testing Market The Point-of-Care Glucose Testing Market is experiencing significant growth, fueled by increasing rates of diabetes globally and a shift towards more accessible healthcare solutions. As patients and healthcare providers seek easier and more accurate ways to manage diabetes, this market is expected to thrive,...

Continue Reading
Artesian Resources Corporation Celebrates Strong Growth in 2025

Updated Category News Views 182

Artesian Resources Corporation's Impressive Performance Artesian Resources Corporation (NASDAQ: ARTNA), a distinguished provider of water and wastewater services on the Delmarva Peninsula, has recently disclosed its remarkable financial performance for the third quarter and year-to-date of 2025. The reports reveal significant increases in both revenue and net income,...

Continue Reading